CRNX Valuation

Crinetics Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

30.920

+1.52(5.170%)1D

Overview
Forecast
Valuation
Earnings

CRNX Relative Valuation

CRNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRNX is overvalued; if below, it's undervalued.

Historical Valuation

Crinetics Pharmaceuticals Inc (CRNX) is now in the Fair zone, suggesting that its current forward PS ratio of 141.10 is considered Fairly compared with the five-year average of -8.02. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between 9.96 to 604.35 according to relative valuation methord.

Relative Value

Fair Zone

9.96-604.35

Current Price：29.94

Fair

-5.63

Trailing

Forward

-3.27

EV/EBITDA

Crinetics Pharmaceuticals Inc. (CRNX) has a current EV/EBITDA of -3.27. The 5-year average EV/EBITDA is -5.38. The thresholds are as follows: Strongly Undervalued below -11.31, Undervalued between -11.31 and -8.35, Fairly Valued between -2.42 and -8.35, Overvalued between -2.42 and 0.54, and Strongly Overvalued above 0.54. The current Forward EV/EBITDA of -3.27 falls within the Historic Trend Line -Fairly Valued range.

-3.00

EV/EBIT

Crinetics Pharmaceuticals Inc. (CRNX) has a current EV/EBIT of -3.00. The 5-year average EV/EBIT is -5.65. The thresholds are as follows: Strongly Undervalued below -11.35, Undervalued between -11.35 and -8.50, Fairly Valued between -2.80 and -8.50, Overvalued between -2.80 and 0.05, and Strongly Overvalued above 0.05. The current Forward EV/EBIT of -3.00 falls within the Historic Trend Line -Fairly Valued range.

139.47

Crinetics Pharmaceuticals Inc. (CRNX) has a current PS of 139.47. The 5-year average PS is 931.50. The thresholds are as follows: Strongly Undervalued below -1586.93, Undervalued between -1586.93 and -327.72, Fairly Valued between 2190.71 and -327.72, Overvalued between 2190.71 and 3449.92, and Strongly Overvalued above 3449.92. The current Forward PS of 139.47 falls within the Historic Trend Line -Fairly Valued range.

-7.57

P/OCF

Crinetics Pharmaceuticals Inc. (CRNX) has a current P/OCF of -7.57. The 5-year average P/OCF is -9.73. The thresholds are as follows: Strongly Undervalued below -18.16, Undervalued between -18.16 and -13.94, Fairly Valued between -5.52 and -13.94, Overvalued between -5.52 and -1.31, and Strongly Overvalued above -1.31. The current Forward P/OCF of -7.57 falls within the Historic Trend Line -Fairly Valued range.

-6.69

P/FCF

Crinetics Pharmaceuticals Inc. (CRNX) has a current P/FCF of -6.69. The 5-year average P/FCF is -9.14. The thresholds are as follows: Strongly Undervalued below -16.57, Undervalued between -16.57 and -12.86, Fairly Valued between -5.43 and -12.86, Overvalued between -5.43 and -1.71, and Strongly Overvalued above -1.71. The current Forward P/FCF of -6.69 falls within the Historic Trend Line -Fairly Valued range.

Crinetics Pharmaceuticals Inc (CRNX) has a current Price-to-Book (P/B) ratio of 2.34. Compared to its 3-year average P/B ratio of 3.78 , the current P/B ratio is approximately -38.16% higher. Relative to its 5-year average P/B ratio of 3.61, the current P/B ratio is about -35.33% higher. Crinetics Pharmaceuticals Inc (CRNX) has a Forward Free Cash Flow (FCF) yield of approximately -11.03%. Compared to its 3-year average FCF yield of -8.70%, the current FCF yield is approximately 26.85% lower. Relative to its 5-year average FCF yield of -9.24% , the current FCF yield is about 19.45% lower.

2.36

P/B

Median3y

3.78

Median5y

3.61

-11.16

FCF Yield

Median3y

-8.70

Median5y

-9.24

Competitors Valuation Multiple

The average P/S ratio for CRNX's competitors is 70.65, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of 139.47, which is 97.41% above the industry average. Given its robust revenue growth of 158.40%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CRNX.O

Crinetics Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

Xenon Pharmaceuticals Inc

Loss

2.99B

LGND.O

Ligand Pharmaceuticals Inc

NewAmsterdam Pharma Company NV

264.28

740.06%

2.82B

Performance Decomposition

Market capitalization of CRNX decreased by 41.73% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 399.00K to 1.03M.

The secondary factor is the Margin Expansion, contributed -39.57%to the performance.

Overall, the performance of CRNX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

158.40%

399.00K → 1.03M

Revenue Growth

-39.57%

-18.56K → -11.22K

Margin Expansion

-160.56%

11.77 → -7.13

P/E Change

-41.73%